Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 40 for:    Terbinafine

Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01851590
Recruitment Status : Completed
First Posted : May 10, 2013
Results First Posted : November 30, 2015
Last Update Posted : November 30, 2015
Sponsor:
Collaborator:
Repolar Ltd.
Information provided by (Responsible Party):
Janne J. Jokinen, Helsinki University Central Hospital

Tracking Information
First Submitted Date  ICMJE May 8, 2013
First Posted Date  ICMJE May 10, 2013
Results First Submitted Date  ICMJE March 20, 2015
Results First Posted Date  ICMJE November 30, 2015
Last Update Posted Date November 30, 2015
Study Start Date  ICMJE October 2013
Actual Primary Completion Date October 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 24, 2015)
Mycological Cure [ Time Frame: At 4- and 10 months time-points from the beginning of the study. ]
To analyze the rate of complete mycological cure i.e. fungal eradication in terms of negative mycological culture AND negative potassium hydroxide (KOH) stain at 4- and 10 months time-points from the beginning of the study.
Original Primary Outcome Measures  ICMJE
 (submitted: May 9, 2013)
Mycological Cure [ Time Frame: August 2013 - May 2014 ]
To analyze the rate of mycological cure i.e. fungal eradication in terms of mycological culture and potassium hydroxide (KOH) stain during the treatment period.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 24, 2015)
  • Clinical Responses to the Treatments [ Time Frame: At 4- and 10 months time-points from the beginning of the study. ]
    Clinical responses to treatment were based on the proximal linear growth of healthy nail; thus, the clinical responses were classified as partial (evident proximal linear growth of healthy nail) or complete. Partial responses were defined as significant reductions in onycholysis, subungual hyperkeratosis, and streaks. A complete response was a fully normal appearance of the toenail.
  • Cost-effectiveness 1 [ Time Frame: At 10-month time-point ]
    Cost analysis was based on the retail price (€) and consumption of a 10 ml bottle of Abicin® 30% resin lacquer, a 5 ml bottle of Loceryl® 5% amorolfine lacquer, and 98 tablets of generic 250 mg terbinafine, sold by the University Pharmacy in Helsinki, Finland, January 2014. The cost was expressed as the average treatment cost per patient; for the total cost, this average was extrapolated to the entire study treatment arm. The results show the treatment costs (€) per day per patient in each group.
  • Cost-effectiveness 2 [ Time Frame: At 10-month time-point ]
    Cost analysis was based on the retail price (€) and consumption of a 10 ml bottle of Abicin® 30% resin lacquer, a 5 ml bottle of Loceryl® 5% amorolfine lacquer, and 98 tablets of generic 250 mg terbinafine, sold by the University Pharmacy in Helsinki, Finland, January 2014. The cost was expressed as the average treatment cost per patient; for the total cost, this average was extrapolated to the entire study treatment arm. The results show the treatment costs (€) during the treatment period per patient in each group.
  • Compliance to the Treatment [ Time Frame: At 4-month time-point ]
    Evaluation of compliance was based on patient self-reports of whether the treatment protocol was followed 100% (complete), 80% (good), 60% (moderate), or 40% (poor) of the time.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 9, 2013)
Clinical cure [ Time Frame: August 2013 - May 2014 ]
To assess objective and subjective clinical treatment result according to the clinical classification of onychomycosis.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures
 (submitted: May 9, 2013)
  • Compliance [ Time Frame: August 2013 - May 2014 ]
    To determine patients' compliance to topical and oral treatment of onychomycosis.
  • Costs [ Time Frame: August 2013 - May 2014 ]
    To assess and compare the total costs of topical and oral treatment.
 
Descriptive Information
Brief Title  ICMJE Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
Official Title  ICMJE Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial
Brief Summary The current study is conducted to corroborate the previous observational clinical trial with more valid methods and a more clinically relevant experimental design. This study aims to compare efficacy, safety, and cost between topically administered 30% resin lacquer for the treatment of dermatophyte toenail onychomycosis and the current "best practices": topical 5% amorolfine and systemic terbinafine.
Detailed Description

The aim of this prospective, investigator-blinded, randomized and controlled clinical trial is to explore potential differences between 5 % amorolfine and 30 % resin lacquer in topical treatment of onychomycosis. In addition, topical treatment methods are compared with the most effective 'drug of choice' for onychomycosis according the current guidelines i.e. oral medication with terbinafine.

Altogether 90 patients (the aim is to collect the 30 patients per group) who have culture or potassium hydroxide (KOH) stain verified dermatophyte onychomycosis are randomly allocated into 3 treatment groups to receive either topical treatment or oral medication for toenail onychomycosis classified as follows:

  1. White superficial onychomycosis (WSO)
  2. Distal and lateral subungual onychomycosis (DLSO)
  3. Proximal subungual onychomycosis (PSO)
  4. [Total dystrophic onychomycosis) (TDO)] [Excluded]
  5. [Candidal onychomycosis] [Excluded]

Participants are randomized into 3 groups to receive:

  1. Topical treatment: 30 % resin lacquer (Abicin®) applied once daily for 9 months.
  2. Topical treatment: 5 % amorolfine lacquer (Loceryl®) applied once weekly for 9 months.
  3. Oral medication: 250 mg terbinafine taken orally once daily for 3 months.

All patients visit at outpatient department before the launch of the study, and 3 and 9 months thereafter. Clinical examination is done by 4 physicians. During the 42-week study period, laboratory tests are conducted on samples collected before treatment, at 20 weeks, and at 42 weeks. The tests include a fungal culture, KOH staining of the toenail sample, and blood tests. Cultures and KOH microscopy are performed in an independent, specialised mycology laboratory with standard techniques (Medix Laboratories Ltd., Helsinki, Finland). The blood tests measure plasma γ-glutamyl transferase levels (also at 2 weeks); plasma creatinine levels; the total number of white blood cells, including neutrophils, monocytes, basophils, lymphocytes, and eosinophils; the total number of red blood cells, including erythrocytes and haematocrit; erythrocyte indices, including the mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, and haemoglobin level; and the total number thrombocytes (initially and at 42 weeks). During the control visits, sequential digital photographs of the most disfigured and brittle toenails are acquired.

In the three phone calls, patients are asked about potential treatment-related side effects, compliance with treatment, patients' perception of treatment outcome, and their willingness to continue in the study. In each treatment arm, the treatment regimen is discontinued 5 weeks before the last toenail sampling to provide an appropriate washout period before the final culture and KOH analysis.

To ensure safety and to assess potential contraindications for the treatment regimens, all patients included in the study undergo a comprehensive medical interview and physical examination. To identify patients who may develop intolerable adverse events due to drug combinations, all concurrent medications are cross-checked to verify compatibility with resin, amorolfine, and terbinafine regimens at the beginning of the study. All patients are informed of the possibility of developing a hypersensitivity to resin, amorolfine, or terbinafine. If patients experienced symptoms that corresponded to any level of hypersensitivity, they are dropped from the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Onychomycosis
Intervention  ICMJE
  • Device: Resin Lacquer
    30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
    Other Name: Resin Lacquer arm
  • Drug: Amorolfine
    5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
    Other Name: Amorolfine Lacquer arm
  • Drug: Terbinafine
    250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
    Other Name: Terbinafine arm
Study Arms  ICMJE
  • Experimental: Resin Lacquer
    Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
    Intervention: Device: Resin Lacquer
  • Active Comparator: Amorolfine
    Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
    Intervention: Drug: Amorolfine
  • Active Comparator: Terbinafine
    250 mg of Terbinafine taken orally once daily for 3 months (Generics).
    Intervention: Drug: Terbinafine
Publications * Sigurgeirsson B et al. Efficacy of amorfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 2010;24: 910-5. Rautio M et al. Antibacterial effects of home-made resin salve from Norway spruce (Picea abies). APMIS 2007;115: 335-340. Rautio M et al. In vitro fungistatic effects of natural coniferous rosin from Norway spruce (Picea abies). Eur J Clin Microbiol Infect Dis 2012;31:1783-9. Sipponen A et al. Effects of Norway spruce (Picea abies) resin on cell wall and cell membrane of Staphylococcus aureus. Ultrastruct Pathol 2009;33: 128-135. Sipponen P et al. Natural coniferous resin lacquer in treatment of toenail onychomycosis: an observational study. Mycoses 2012, Accepted. Roberts DT et al. British Association of Dermatologists. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10. Baran R et al. A new classification of onychomycosis. Br J Dermatol 1998;139: 567-71.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 24, 2015)
129
Original Estimated Enrollment  ICMJE
 (submitted: May 9, 2013)
90
Actual Study Completion Date  ICMJE October 2014
Actual Primary Completion Date October 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Positive dermatophyte culture in the beginning of the study obtained from the toenail sample.
  • Positive KOH stain in the beginning of the study obtained from the toenail sample.

Exclusion Criteria:

  • Any other nail disease than dermatophyte culture or KOH stain verified onychomycosis
  • Onychomycosis caused by yeasts or nondermatophyte molds
  • Kidney failure determined by plasma creatinine level (P-Krea > 100 μmol/l)
  • Liver failure determined by plasma γ-glutamyltransferase level (P-GT > 120 U/I)
  • Sensitivity or allergy to Resin, Amorolfine or Terbinafine
  • Potential adverse cross-reaction of Terbinafine, Amorolfine or Resin with the patient's permanent medication
  • Presence of total dystrophic onychomycosis (TDO)
  • Any topical or oral antifungal treatment within the 6 months before the beginning of the study (washout period > 6 months).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Finland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01851590
Other Study ID Numbers  ICMJE 334/13/03/01/2012
2012-004822-48 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Janne J. Jokinen, Helsinki University Central Hospital
Study Sponsor  ICMJE Helsinki University Central Hospital
Collaborators  ICMJE Repolar Ltd.
Investigators  ICMJE
Principal Investigator: Janne J. Jokinen, MD, PhD Department of Cardiac Surgery, Heart and Lung Centre, Helsinki University Hospital, FI-00029, Helsinki, Finland
PRS Account Helsinki University Central Hospital
Verification Date October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP